Characteristics of the patients
| Patient . | Age, y . | Sex . | Cutaneous lesion . | Medullary blasts . | Initial NGS . | Karyotype . | CNS involved . | Status after C1 . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 84 | M | Yes | 83% | KRAS, ETV6, SRSF2, TET2 | 12q alteration | No | CR | Dead |
| 2 | 78 | M | Yes | 73% | TET2, ASXL1, ZRSR2, ETV6 | Complex, monosomal | No | CR | Dead |
| 3 | 77 | M | No | 76% | TET2, TP53 | Complex | Yes | CRi with persistent neutropenia | Dead |
| 4 | 81 | M | Yes | 99% | n/a | t(X;13), -9, -13 | No | CR | Alive |
| 5 | 71 | F | Yes | 12% | n/a | n/a | No | CR | Dead |
| 6 | 80 | M | Yes | 1% | ASXL1, SRSF2, TET2 | n/a | Yes | CRi with persistent neutropenia | Dead |
| 7 | 78 | M | Yes | 81% | PTPN11, SRSF2, TET2, ZRSR2 | 46,XY | Yes | CR | Dead |
| 8 | 76 | M | Yes | 2% | n/a | n/a | No | CR | Alive |
| 9 | 49 | M | Yes | 0% | KMT2A, KMT2D, MS4A1, EP300 | n/a | No | CR on PET scan | Alive |
| 10 | 71 | M | Yes | 75% | No mutations | 45,XY,add(5)(q31),?del(6)(q22q24),-15[5]/46,XY(15) | No | CR | Alive |
| 11 | 67 | M | Yes | 98% | TET2, ASXL1 | n/a | Yes | CRi with persistent thrombocytopenia | Alive |
| 12 | 71 | M | No | 97% | TET2, ASXL1, SRSF2, RUNX1 | n/a | Yes | CR | Alive |
| Patient . | Age, y . | Sex . | Cutaneous lesion . | Medullary blasts . | Initial NGS . | Karyotype . | CNS involved . | Status after C1 . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 84 | M | Yes | 83% | KRAS, ETV6, SRSF2, TET2 | 12q alteration | No | CR | Dead |
| 2 | 78 | M | Yes | 73% | TET2, ASXL1, ZRSR2, ETV6 | Complex, monosomal | No | CR | Dead |
| 3 | 77 | M | No | 76% | TET2, TP53 | Complex | Yes | CRi with persistent neutropenia | Dead |
| 4 | 81 | M | Yes | 99% | n/a | t(X;13), -9, -13 | No | CR | Alive |
| 5 | 71 | F | Yes | 12% | n/a | n/a | No | CR | Dead |
| 6 | 80 | M | Yes | 1% | ASXL1, SRSF2, TET2 | n/a | Yes | CRi with persistent neutropenia | Dead |
| 7 | 78 | M | Yes | 81% | PTPN11, SRSF2, TET2, ZRSR2 | 46,XY | Yes | CR | Dead |
| 8 | 76 | M | Yes | 2% | n/a | n/a | No | CR | Alive |
| 9 | 49 | M | Yes | 0% | KMT2A, KMT2D, MS4A1, EP300 | n/a | No | CR on PET scan | Alive |
| 10 | 71 | M | Yes | 75% | No mutations | 45,XY,add(5)(q31),?del(6)(q22q24),-15[5]/46,XY(15) | No | CR | Alive |
| 11 | 67 | M | Yes | 98% | TET2, ASXL1 | n/a | Yes | CRi with persistent thrombocytopenia | Alive |
| 12 | 71 | M | No | 97% | TET2, ASXL1, SRSF2, RUNX1 | n/a | Yes | CR | Alive |
C1, cycle 1; CNS, central nervous system; CR: hematologic complete response; CRi, complete remission with incomplete count recovery; F, female; M, male; n/a, not applicable; NGS, next generation sequencing; PET, positron emission tomography.